BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Melanoma clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for melanoma: 262 (174 sponsors; 18 newly posted in the last 180 days, 14 stopped in the last 180 days; 8 new-entrant sponsors). Momentum score 7.6, rank 84 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 75, Phase 2 108, Phase 3 38, Phase 4 2, N/A 36.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Regeneron Pharmaceuticals REGN | 9 | P3 4, P2 5 | 2 | 2 |
| Bristol-Myers Squibb BMY | 9 | P2 3, NA 2, P3 3, P4 1 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 6 | P2 3, P3 3 | 0 | 0 |
| IDEAYA Biosciences IDYA | 5 | P2 2, P3 3 | 1 | 3 |
| Biocad | 4 | P3 3, P1 1 | 0 | 1 |
| Replimune, Inc. REPL | 5 | P2 1, NA 1, P1 1, P3 2 | 0 | 0 |
| Philogen S.p.A. | 3 | P2 1, P3 2 | 0 | 0 |
| Immunocore Ltd IMCR | 2 | P3 2 | 0 | 0 |
| Aura Biosciences AURA | 4 | P3 1, NA 3 | 0 | 0 |
| Iovance Biotherapeutics, Inc. IOVA | 4 | P2 3, P3 1 | 0 | 0 |
| Pfizer PFE | 4 | P3 1, P1 3 | 0 | 0 |
| Immatics US, Inc. IMTX | 3 | P2 1, P1 1, P3 1 | 0 | 0 |
| Binhui Biopharmaceutical Co., Ltd. | 2 | P2 1, P3 1 | 0 | 0 |
| Erasca, Inc. ERAS | 2 | P3 1, P1 1 | 0 | 0 |
| IO Biotech | 2 | P3 1, P2 1 | 0 | 0 |
| Linnaeus Therapeutics, Inc. | 2 | P3 1, P2 1 | 0 | 0 |
| Pierre Fabre Medicament | 2 | P3 1, P1 1 | 0 | 1 |
| Scancell Ltd SCNLD | 2 | P2 1, P3 1 | 1 | 1 |
| Amgen AMGN | 1 | P3 1 | 0 | 0 |
| Delcath Systems Inc. DCTH | 1 | P3 1 | 0 | 0 |
| Eikon Therapeutics EIKN | 1 | P3 1 | 0 | 0 |
| HUYABIO International, LLC. | 1 | P3 1 | 0 | 0 |
| mAbxience Research S.L. | 1 | P3 1 | 0 | 1 |
| Shanghai Kechow Pharma, Inc. | 1 | P3 1 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 6 | P2 2, P1 2, P4 1, NA 1 | 0 | 1 |
Recently stopped trials
- NCT05879822 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- NCT05529316 Agenus Inc. - terminated: Sponsor decision A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
- NCT06566092 Iovance Biotherapeutics, Inc. - terminated: After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits. Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- NCT03881488 Compass Therapeutics - terminated: The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metasta
- NCT06984328 Genmab - terminated: Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin
- NCT05665595 Merck Sharp & Dohme LLC - terminated: Business Reason A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Partic
- NCT01029873 Altor BioScience - terminated: Sponsor decision QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
- NCT07076550 Alpha-9 Oncology USA Inc. - terminated: Due to a strategic decision to re-prioritize the sponsor's existing portfolio. A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Mela
- NCT06171178 Astellas Pharma Global Development, Inc. - terminated: Due to strategic decision made by the sponsor the study was terminated A Study of ASP1012 in Adults With Solid Tumors
- NCT03114319 Novartis Pharmaceuticals - terminated: Business reasons and not due to any safety concerns Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
- NCT05571839 Seagen, a wholly owned subsidiary of Pfizer - terminated: The trial was terminated for strategic reasons. The decision was not based on any safety concerns. A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- NCT05130255 Y-mAbs Therapeutics - terminated: Decision by Sponsor GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
- NCT04695977 Regeneron Pharmaceuticals - terminated: Business Decision CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
- NCT04458259 Pfizer - terminated: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | Shanghai JMT-Bio Inc. | NCT07280832 Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors | Unresectable Locally Advanced or Metastatic Melanoma; Unresectable Locally Advanced or Metastatic Ur | recruiting | 500 |
| 2026-12 est. | P1/P2 | Sapience Therapeutics | NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain | active not recruiting | 125 |
| 2026-12 est. | P1/P2 | Beijing Scitech-Mq Pharmaceuticals Limited | NCT06359860 A Study of ST-1898 for Unresectable or Metastatic Melanoma | Unresectable or Metastatic Melanoma | active not recruiting | 64 |
| 2026-12 est. | P1/P2 | Georgiamune Inc | NCT06425926 Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Melanoma Stage IV; Solid Tumor | recruiting | 117 |
| 2026-12-15 est. | P1/P2 | GV20 Therapeutics | NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; | recruiting | 365 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06797297 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal | Melanoma | active not recruiting | 203 |
| 2027-01 est. | P3 | Biocad | NCT05751928 A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | Melanoma Stage III; Melanoma (Skin) | active not recruiting | 411 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-15 est. | P3 | Regeneron Pharmaceuticals REGN | NCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has | Melanoma | active not recruiting | 1564 |
| 2027-01-15 est. | P2/P3 | IDEAYA Biosciences IDYA | NCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | active not recruiting | 420 |
| 2027-01-29 est. | P1/P2 | IDEAYA Biosciences IDYA | NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors | recruiting | 336 |
| 2027-01-31 est. | P2 | Scancell Ltd SCNLD | NCT04079166 SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | Malignant Melanoma; Melanoma (Skin); Melanoma Stage III; Melanoma Stage IV | active not recruiting | 173 |
| 2027-02-02 est. | P2 | Novartis Pharmaceuticals NVS | NCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Melanoma | active not recruiting | 134 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-07-30 | FDA AdCom | held | Replimune, Inc. REPL | AdCom 2026-07-30: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125827 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-02 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | Melanoma | active not recruiting | 151 |
| 2026-10-30 est. | P3 | Pfizer PFE | NCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Melanoma | active not recruiting | 257 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-13 est. | P1/P2 | GlaxoSmithKline | NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrin | active not recruiting | 83 |
| 2026-10 est. | P2 | Vyriad, Inc. | NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Melanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Cancer | active not recruiting | 87 |
| 2026-09-30 est. | P1/P2 | Shanghai Pharmaceuticals Holding Co., Ltd | NCT06214156 A Clinical Study of T3011 in Subjects With Advanced Melanoma | Advanced Melanoma | recruiting | 42 |
| 2026-09-22 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Me | Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC | recruiting | 30 |
| 2026-09-09 | P1/P2 | BioInvent International AB | NCT06784648 Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | Melanoma Metastatic; Melanoma of Skin; Melanoma BRAF V600E/K Mutated; Melanoma Recurrent; Melanoma S | active not recruiting | 35 |
| 2026-08-01 est. | P1/P2 | OncoResponse, Inc. | NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanom | recruiting | 168 |
| 2026-07 est. | P1/P2 | CJ Bioscience, Inc. | NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancer | recruiting | 160 |
| 2026-07 est. | P3 | HUYABIO International, LLC. | NCT04674683 Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | Unresectable or Metastatic Melanoma; Progressive Brain Metastasis | active not recruiting | 450 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06-02 | P1/P2 | Binhui Biopharmaceutical Co., Ltd. | NCT04386967 OH2 Injection in Solid Tumors | Solid Tumor; Melanoma | completed | 44 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06500091 TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors | Soft Tissue Sarcoma; Melanoma | not yet recruiting | 54 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "melanoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.